Atara Biotherapeutics (ATRA) Projected to Post Quarterly Earnings on Monday

Atara Biotherapeutics (NASDAQ:ATRA) is projected to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $4.23 million for the quarter.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, May 15th. The biotechnology company reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.07) by $6.57. The company had revenue of $98.10 million during the quarter, compared to the consensus estimate of $4.30 million. On average, analysts expect Atara Biotherapeutics to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ ATRA opened at $10.95 on Friday. The company has a market cap of $65.26 million, a P/E ratio of -2.94 and a beta of 0.26. The firm’s fifty day moving average is $9.51 and its two-hundred day moving average is $7.99. Atara Biotherapeutics has a 52-week low of $5.01 and a 52-week high of $18.70.

Insider Transactions at Atara Biotherapeutics

In related news, major shareholder Innovation Ltd Panacea purchased 19,335 shares of Atara Biotherapeutics stock in a transaction on Thursday, July 17th. The shares were bought at an average cost of $9.64 per share, for a total transaction of $186,389.40. Following the acquisition, the insider owned 1,350,000 shares in the company, valued at approximately $13,014,000. The trade was a 1.45% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.00% of the company’s stock.

Institutional Trading of Atara Biotherapeutics

An institutional investor recently raised its position in Atara Biotherapeutics stock. Geode Capital Management LLC increased its stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 2.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,136 shares of the biotechnology company’s stock after acquiring an additional 1,457 shares during the period. Geode Capital Management LLC owned approximately 1.01% of Atara Biotherapeutics worth $464,000 as of its most recent SEC filing. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.